TamaBio has received a notice of grant decision for subsidy to support the international patent application for our domestic joint patent inventions with Tohoku University [Regenerative Medical Devices – Brain Tissue etc. Damage Repair Sheet].
TamaBio will be sponsoring the 57th Spine Surgery Club Meeting to be held on Aug.23rd at Nagasaki.
Nippon Medical School and TamaBio Sign New Joint Research Agreement : Regenerative Therapy for Infarcted Myocardium Using Epicardial Approach
Tamabio Co., Ltd. opened an account on “X”.
Biocompatibility and Tissue Regeneration Ability of the artificial dura mater DuraBeam was presented at CNTT2025/JSAN2025, Osaka International Convention Center
FDA Cleared : “PeriBeam” Pericardial Membrane
TamaBio has completed capital increase through third-party allotment (Round B).
An Advanced Research Presentation on the Biocompatibility and Tissue Regeneration Ability of DuraBeam®, the artificial dura mater, will be held at JSAN2025 (The 18th Annual Meeting of the Japanese Society of Aesthetic Neurosurgery, April 18th (Fri) – 19th (Sat), 2025).
Touch samples of the synthetic artificial dura mater “DuraBeam®” will be exhibited at STROKE2025 (50th Annual Meeting of the Japan Stroke Society; Thursday, March 6th to Saturday, March 8th, 2025).
“DuraBeam®” was exhibited at the 48th Japanese Society of Neurotraumatology (Friday, February 21st to Saturday, February 22nd, 2025).
